Medtronic plc
NYSE:MDTMedical - Devices
+$0.75 today
- Market cap
- $128.84B
- Beta
- 0.60
- P/E (TTM)
- 21.1
- EPS (TTM)
- $3.74
- Dividend yield
- 3.60%
Volume 6.47M
Average 11.36M
MDT Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Medtronic plcNYSE: MDT
Free Cash Flow · Q1 FY2027 · quarter ended Jul 2026
Free cash flow growth accelerates
Q1 FY2027 free cash flow of $1.29B rose 120.9% year over year, ahead of the +15.6% change in trailing-twelve-month free cash flow. Sequentially, it fell 38.1% from the prior quarter. Over 3 fiscal years it compounded at +5.8% a year.
Context
- Free cash flow amounted to 14.9% of revenue in FY2026, down 0.5 pp from a year earlier.
- Free cash flow increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +120.9% holds above the trailing-twelve-month pace of +15.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2026
- 5.43B USD
- Year-over-year change
- +4.6%
- 4-year CAGR
- -2.4%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2026 | 2026-04-24 | 5.43B | +4.6% |
| FY2025 | 2025-04-25 | 5.19B | -0.3% |
| FY2024 | 2024-04-26 | 5.2B | +13.5% |
| FY2023 | 2023-04-28 | 4.58B | -23.4% |
| FY2022 | 2022-04-29 | 5.98B | — |
Free Cash Flow vs competitors
How MDT compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.6% is the 7th highest of 9, against a peer median of +27.1%.
- Free cash flow amounts to 16.3% of revenue for MDT, versus a peer median of 17.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $6.13B USD | +15.6% | +5.8% | 16.3% | |
| LTM Jun 2026 | $4.7B USD | +16.8% | +28.1% | 18.2% | |
| LTM Jun 2026 | $3.63B USD | +9.5% | +58.8% | 17.3% | |
| LTM Jun 2026 | €1.9B EUR | +334.4% | — | 10.8% | |
| LTM Jun 2026 | $1.83B USD | +28.5% | +11.3% | 21.5% | |
| LTM Jun 2026 | $1.43B USD | +135.8% | +11.9% | 22.0% | |
| LTM Jun 2026 | $215.91M USD | +33.6% | — | 14.3% | |
| LTM Sep 2026 | $128.96M USD | -32.6% | +58.6% | 8.6% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $86.69M USD | +25.6% | +36.9% | 4683.3% |
| Peer median (excluding MDT) | — | +27.1% | +32.5% | 17.7% | |
Competitors are the stored peer set for MDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Apr 2026 |
|---|---|---|---|---|---|
| Net Income | 5.06B | 3.78B | 3.68B | 4.69B | 4.84B |
| Depreciation & Amortization | 2.71B | 2.7B | 2.65B | 2.86B | 2.96B |
| Deferred Income Tax | (604M) | (226M) | (508M) | (316M) | 51M |
| Stock-Based Compensation | 359M | 355M | 393M | 429M | 457M |
| Change in Working Capital | (889M) | (967M) | (484M) | (1.05B) | (1.42B) |
| Accounts Receivables | (477M) | (576M) | (391M) | (433M) | (200M) |
| Inventory | (560M) | (939M) | (139M) | (292M) | (404M) |
| Accounts Payables | 213M | 696M | 391M | 209M | 46M |
| Other Working Capital | (65M) | (148M) | (345M) | (538M) | (865M) |
| Other Non-Cash Items | 711M | 396M | 1.06B | 433M | 450M |
| Operating Cash Flow | 7.35B | 6.04B | 6.79B | 7.04B | 7.33B |
| Capital Expenditures | (1.37B) | (1.46B) | (1.59B) | (1.86B) | (1.9B) |
| Acquisitions (Net) | (91M) | (1.87B) | (211M) | (98M) | (406M) |
| Purchases of Investments | (9.88B) | (7.51B) | (7.75B) | (8.23B) | (8.73B) |
| Sales of Investments | 9.69B | 7.34B | 7.44B | 8.5B | 8.11B |
| Other Investing Activities | (10M) | 4M | (261M) | (249M) | (4M) |
| Investing Cash Flow | (1.66B) | (3.49B) | (2.37B) | (1.94B) | (2.93B) |
| Debt Repayment | (1M) | (598M) | 1.07B | 2.14B | (1.17B) |
| Common Stock Issued | 429M | 308M | 284M | 508M | 516M |
| Common Stock Repurchased | (2.54B) | (645M) | (2.14B) | (3.24B) | (1.04B) |
| Dividends Paid | (3.38B) | (3.62B) | (3.67B) | (3.59B) | (3.64B) |
| Other Financing Activities | 163M | (101M) | (3M) | (184M) | 582M |
| Financing Cash Flow | (5.34B) | (4.96B) | (4.45B) | (4.36B) | (4.75B) |
| Effect of Forex Changes | (230M) | 243M | (230M) | 188M | 85M |
| Net Change in Cash | 121M | (2.17B) | (259M) | 934M | (269M) |
| Free Cash Flow | 5.98B | 4.58B | 5.2B | 5.19B | 5.43B |
Medtronic plc
NYSE:MDT
Intrinsic Alpha fair value
Locked
Current Price
$100.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.